Skip to main content

Table 1 Overview of meta-analyses of the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in solid tumours

From: Neutrophils in cancer: prognostic role and therapeutic strategies

Reference

Prognostic outcome for high NLR: If not otherwise indicated, Hazard Ratio [95% confidence interval]

PubMed identifier

Author

Tumor type

Number of studies

Number of patients

OS

PFS

DFS/RFS

EFS

PMID: 27,368,058

Cao J. et al.

Prostate cancer

22

18,092

1.40 [1.25–1.55]

1.42 [1.23–1.61]

1.38 [1.01–1.75]

-

PMID: 25,889,889

Chen J. et al.

Gastric cancer

9

3709

2.16 [1.86–2.50]

2.78 [1.95–3.96]

-

-

PMID: 28,430,605

Chen N. et al.

Malignant pleural mesothelioma

11

1533

1.48 [1.16–1.89]

-

-

-

PMID: 26,226,887

Cheng H. et al.

Pancreatic cancer

9

2035

1.59 [1.41–1.79]

-

-

-

PMID: 28,693,795

Dolan R.D. et al.

Advanced inoperable cancer

59

16,921

1.71 [1.57–1.86]

-

-

-

PMID: 28,222,899

Ethier J.L. et al.

Gynecologic cancer

26

10,530

1.65 [1.44–1.89]

-

-

1.57 [1.35–1.82]

PMID: 26,912,340

Gu X. et al.

Prostate cancer

14

16,266

1.38 [1.22–1.56]

1.24 [1.05–1.46]

-

-

PMID: 26,205,001

Gu X.B. et al.

Non- small cell lung cancer

14

3656

1.70 [1.39–2.09]

1.63 [1.27–2.09]

-

-

PMID: 25,854,964

Hu K. et al.

Renal cell carcinoma

15

3357

1.82 [1.51–2.19]

2.18 [1.75–2.71]

-

-

PMID: 28,467,978

Huang Q.T. et al.

Ovarian cancer

12

3854

1.69 [1.29–2.22]

1.63 [1.27–2.09]

-

-

PMID: 28,187,430

Huang Q.T. et al.

Cervical cancer

9

2804

1.88 [1.30–2.73]

1.65 [1.18–2.29]

-

-

PMID: 24,122,750

Li M.X. et al.

Colorectal cancer

16

6859

1.81 [1.50–2.19]

2.10 [1.55–2.84]

-

-

PMID: 28,514,738

Li X. et al.

Upper urinary tract and bladder

32

11,538

1.72 [1.45–2.05]

1.68 [1.44–1.96]

-

-

PMID: 26,835,589

Li Y. et al.

Soft tissue sarcoma

11

1809

3.75 [1.24–11.37]

-

2.43 [0.84 –7.05]

-

PMID: 26,448,011

Luo Y. et al.

Renal cell carcinoma

34

9811

1.79 [1.61–2.00]

1.85 [1.24–2.77]

1.97 [1.37–2,84]

-

  

Upper tract urothelial carcinoma

  

2.48 [1.31–4.70]

1.70 [1.14–2.56]

1.47 [1.11–1.95]

-

  

Bladder cancer

  

1.68 [1.45–1.94]

3.52 [1.33–9.33]

1.55 [1.21–2.00]

-

  

Prostate cancer

  

1.44 [1.28–1.62]

1.29 [1.04–1.59]

-

-

PMID: 24,866,438

Malietzis G. et al.

Colorectal cancer

13

4056

-

-

2.08 [1.64–2.64]

-

PMID: 28,131,752

Marchioni M. et al.

Upper tract urothelial cancer

6

1710

1.97 [1.27–3.04]

-

1.53 [1.19–1.96]

-

PMID: 28,602,879

Mei Z. et al.

Advanced cancer

66

24,536

1.70 [1.57–1.84]

-

1.61 [1.42–1.82]

-

PMID: 27,270,655

Na N. et al.

Renal carcinoma

9

1091

1.93 [1.35–2.77]

2.12 [1.42–3.17]

-

-

PMID: 24,378,193

Paramanathan A. et al.

Solid tumors

49

14,282

1.92 [1.64–2.24]

-

1.99 [1.80–2.20]

-

PMID: 26,064,198

Peng B. et al.

Non-small cell lung cancer

12

2377

1.43 [1.25–1.64]

1.37 [1.07–1.74]

-

-

PMID: 28,296,774

Su L. et al.

Nasopharyngeal carcinoma

14

11,651

1.77 [1.41–2.23]

1.67 [1.36–2.06]

-

-

PMID: 26,924,872

Sun J. et al.

Gastric cancer

19

5431

1.98 [1.75–2.24]

1.58 [1.32–1.88]

-

-

PMID: 27,427,969

Tang H. et al.

Colorectal Liver metastasis

8

1685

2.17 [1.82–2.58]

-

1.96 [1.64–2.35]

-

PMID: 27,096,158

Tang L. et al.

Advanced Prostate cancer

18

9418

1.628 [1.41–1.879]

-

1.37 [1.13–1.64]

-

PMID: 24,875,653

Templeton A.J. et al.

Solid tumors

100

40,559

1.81 [1.67–1.97]

1.63 [1.39–1.91]

2.27 [1.85–2.79]

-

PMID: 27,461,614

Tsai P.L. et al.

Colorectal cancer

15

7741

OR: 2.03 [1.56–2.63]

-

OR: 1.67 [1.19–2.35]

-

PMID: 27,660,475

Wei B. et al.

Breast cancer

12

7951

2.03 [1.41–2.93]

-

1.46 [1.12–1.90]

-

PMID: 24,642,859

Wei Y. et al.

Urinary cancer

17

3159

1.81 [1.48–2.21]

-

2.07 [1.65–2.6]

-

PMID: 28,077,792

Wu J. et al.

Cervical cancer

13

3729

1.38 [1.20–1.58]

1.65 [1.31–2.07]

-

-

PMID: 24,559,042

Xiao W.K. et al.

Hepatocellular carcinoma

15

3094

3.42 [2.41–4.85]

-

5.90 [3.99–8.70]

-

PMID: 26,225,826

Xin-Ji Z. et al.

Gastric cancer

29

14,321

1.65 [1.47–1.83]

-

1.61 [1.28–1.94]

-

PMID: 24,788,770

Xue T.C. et al.

Liver cancer

26

4461

2.10 [1.74–2.54]

-

2.47 [1.85–3.30]

-

PMID: 27,732,958

Yang H.B. et al.

Lung cancer

19

7283

1.23 [1.17–1.29]

1.18 [1.08–1.29]

-

-

PMID: 25,759,553

Yang J.J. et al.

Pancreatic cancer

11

1804

2.61 [1.68–4.06]

-

-

-

PMID: 25,914,549

Yang X. et al.

Esophageal cancer

6

1633

1.54 [1.32–1.80]

-

1.74 [1.25–2.43]

-

PMID: 28,423,365

Yang Z. et al.

Epithelial ovarian cancer

12

3154

1.72 [1.18–2.51]

1.80 [1.22–2.65]

-

-

PMID: 26,817,900

Yin X. et al.

Prostate cancer

14

12,474

1.45 [0.77–2.71]

-

1.34 [0.89–2.02]

-

  

Metastatic castration resistant prostate cancer

  

1.57 [1.41–1.74]

1.97 [1.28–3.04]

-

-

PMID: 26,222,823

Yin Y. et al.

Lung cancer

14

2734

1.51 [1.32–1.72]

-

-

-

PMID: 26,416,715

Yodying H. et al.

Esophageal cancer

7

1540

1.40 [1.08–1.81]

-

1.54 [0.79–2.98]

-

PMID: 28,644,143

Zhang J. et al.

Colorectal cancer

23

11,762

1.92 [1.57–2.34]

-

1.66 [1.31–2.11]

-

PMID: 25,401,500

Zhang X. et al.

Gastric cancer

10

2952

1.83 [1.62–2.07]

1.54 [1.22–1.95]

1.58 [1.12–2.21]

-

PMID: 26,491,346

Zhao Q.T. et al.

Lung cancer

22

7054

1.51 [1.33–1.71]

1.33 [1.07–1.67]

-

-

  1. Abbreviations: NLR neutrophil-to-lymphocyte ratio, DFS/RFS Disease-free survival/Recurrence-free survival, PFS Progression-free survival, OS Overall survival, EFS Event-free survival, OR Odds ratio
Back to article page

Molecular Cancer

ISSN: 1476-4598